These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34332789)

  • 1. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
    Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
    Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
    Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
    Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
    Emond B; Sundaram M; Romdhani H; Lefebvre P; Wang S; Mato A
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):763-775.e2. PubMed ID: 31678080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
    Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
    JCO Oncol Pract; 2024 Apr; ():OP2300630. PubMed ID: 38626366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
    Hagiwara M; Panjabi S; Sharma A; Delea TE
    J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
    Huang Q; Deering KL; Harshaw Q; Leslie LA
    Adv Ther; 2022 Jul; 39(7):3292-3307. PubMed ID: 35608754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
    McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
    Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
    Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
    J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
    Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
    Sancho JM; Marín-Niebla A; Fernández S; Capote FJ; Cañigral C; Grande C; Donato E; Zeberio I; Puerta JM; Rivas A; Pérez-Ceballos E; Vale A; Martín García-Sancho A; Salar A; González-Barca E; Teruel A; Pastoriza C; Conde-Royo D; Sánchez-García J; Barrenetxea C; Arranz R; Hernández-Rivas JÁ; Ramírez MJ; Jiménez A; Rubio-Azpeitia E
    Int J Hematol; 2022 Sep; 116(3):381-392. PubMed ID: 35551632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
    Kabadi SM; Byfield SD; LE L; Olufade T
    Anticancer Res; 2021 Feb; 41(2):927-936. PubMed ID: 33517299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
    Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M
    Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
    Vorobyev VI; Gemdzhian EG; Fedorova LV; Mikhailova NB; Ilyasov RK; Kaleikina LP; Trubyakova OS; Kaplanov KD; Melnichenko EV; Martynova EV; Yakovleva EP; Li OY; Tarasenko EV; Chumakova EP; Bulieva NB; Nesterova ES; Margolin OV; Zherebtsova VA; Butaev LS; Ptushkin VV
    Ter Arkh; 2021 Jul; 93(7):770-777. PubMed ID: 36286727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.